Terms of Use

Recent News

ALung Technologies, Inc. (“ALung”) offers this Website, including all information, software, products and services available from this Web site or offered as part of or in conjunction with this Website (the “Website”), to you, the user, conditioned upon your acceptance of all of the terms, conditions, policies and notices stated here. ALung reserves the right … Continued

ALung Initiates Enrollment in Pivotal Trial of the Hemolung RAS for the US Market

Press Release

PITTSBURGH (February 27, 2018) – ALung Technologies, Inc., today announced that it has initiated patient enrollment in its VENT-AVOID Trial of the Hemolung RAS. The Minneapolis Heart Institute Foundation® recently enrolled the first study subject at Abbott Northwestern Hospital in Minneapolis, Minnesota. The VENT-AVOID Trial is the world’s first pivotal trial of extracorporeal carbon dioxide … Continued

ALung Receives IDE Approval to Conduct VENT-AVOID Trial of the Hemolung RAS for the US Market

Press Release

PITTSBURGH (September 27, 2017) – ALung Technologies, Inc., today announced U.S. Food and Drug Administration (FDA) approval of its Investigational Device Exemption (IDE) to conduct a pivotal clinical trial of the Hemolung® Respiratory Assist System for the treatment of adults with severe acute exacerbation of chronic obstructive pulmonary disease (COPD). The FDA’s approval of the … Continued

ALung Submits IDE Application to FDA Seeking Approval to Conduct Pivotal Study of the Hemolung RAS

Press Release

PITTSBURGH (April 25, 2017) – ALung Technologies, Inc., announced today the submission of its Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) seeking approval to conduct a pivotal clinical study of the Hemolung < Respiratory Assist System for the treatment of adults with severe acute exacerbations of chronic obstructive pulmonary … Continued

ALung Technologies Closes $36 Million Financing

Press Release

Investment led by Philips and UPMC to fund pivotal trial of artificial lung technology. PITTSBURGH (April 11, 2017) – ALung Technologies, Inc., the leading provider of low-flow extracorporeal carbon dioxide removal (ECCO2R) technologies for treating patients with acute respiratory failure, announced today the closing of a $36 million Series C financing, including existing convertible notes. … Continued

ALung Technologies Forms Trial Steering Committee

Press Release

Renowned physicians will oversee landmark trial of the Hemolung RAS in patients with COPD. PITTSBURGH (November 15, 2016) – ALung Technologies, Inc., a leading provider of low-flow extracorporeal carbon dioxide removal (ECCO2R) technologies for treating patients with acute respiratory failure, announced today the formation of its Trial Steering Committee (TSC) for its upcoming pivotal trial … Continued